| abstract |
Disclosed is an adjuvanted vaccine compositions where the adjuvant is a liposomal formulation, comprising a saponin and a lipopolysaccharide. Disclosed is an immunogenic composition in a volume suitable for a human dose comprising an antigen, in combination with an adjuvant which adjuvant comprises QS21 presented in the form of a liposome and 3D-MPL wherein said QS21 and said 3D-MPL are both present in said human dose at a level of between 20 micrograms and 30 micrograms. The antigen in the immunogenic composition can be derived from M. tuberculosis, varicella zoster virus (VZV), human cytomegalovirus (HCMV), HIV-1, or Chlamydia spp. |